Publications by authors named "Xiangping Deng"

Claim this Profile
I
Intermediate-dose cytarabine alone versus combination in consolidation therapy for non-transplant acute myeloid leukemia: a retrospective study.
Yu Liu, Zhihui Wang, Tairan Chen, Lixin Zhou, Qiulian He, Xiangping Deng

Ann Med· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reversing the Warburg effect: Discovery of potent pyruvate dehydrogenase kinase inhibitors for inhibiting tumor growth.
Meiyan Tang, Yiyang Li, Pengju Ye, Yanliu Peng, Yijia Tang, Xiangping Deng

Bioorg Chem· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of novel chalcone derivatives containing benzimidazole possessing anti-tumor potential in vitro and in vivo.
Qianyu Wang, Hui Qiao, Weixi Yuan, Xiangping Deng, Zhizhong Xie

Biomed Pharmacother· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advances in the design and application of glycolysis-related nanodelivery systems for anti-tumor.
Yanghui Zhou, Meijing Liu, Na Lu, Xiangping Deng, Xin Chen

Colloids Surf B Biointerfaces· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of novel flavonoid derivatives targeting VEGFR2 and tubulin with potent anticancer efficacy.
Xiang He, Yijiao Peng, Renbo Liu, Weixi Yuan, Pengju Ye, Xiangping Deng

Bioorg Chem· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Research progress of flavonoids targeting estrogen receptor in the treatment of breast cancer.
Jianling Long, Pengju Ye, Weixi Yuan, Qixian Yang, Zhe Wang, Xiangping Deng

Bioorg Med Chem· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intranuclear TCA and mitochondrial overload: The nascent sprout of tumors metabolism.
Weixi Yuan, Guozhong Lu, Yin Zhao, Xiang He, Senyi Liao, Xiangping Deng

Cancer Lett· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to "Structure-guided identification of novel dual-targeting estrogen receptor α degraders with aromatase inhibitory activity for the treatment of endocrine-resistant breast cancer" [Eur. J. Med. Chem. 253 (2023) 115328].
Lilan Xin, Jian Min, Hebing Hu, Yuanyuan Li, Chuanqian Du, Xiaofei Deng, Xiangping Deng

Eur J Med Chem· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Novel ERα and Aromatase Dual-Targeting PROTAC Degraders to Overcome Endocrine-Resistant Breast Cancer.
Lilan Xin, Chao Wang, Yan Cheng, Hongli Wang, Xinyi Guo, Xiaofei Deng, Xiangping Deng

J Med Chem· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Small-molecule modulators of tumor immune microenvironment.
Jing Zhang, Jia Yu, Meijing Liu, Zhizhong Xie, Xiaoyong Lei, Xiangping Deng

Bioorg Chem· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recent advances in pyruvate dehydrogenase kinase inhibitors: Structures, inhibitory mechanisms and biological activities.
Yiyang Li, Zhizhong Xie, Xiaoyong Lei, Xiaoyan Yang, Sheng Huang, Xiangping Deng

Bioorg Chem· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
pH regulators and their inhibitors in tumor microenvironment.
Senyi Liao, Guang Wu, Zhizhong Xie, Xiaoyong Lei, Xiaoyan Yang, Xiangping Deng

Eur J Med Chem· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of novel covalent selective estrogen receptor degraders against endocrine-resistant breast cancer.
Yubo Wang, Jian Min, Xiangping Deng, Tian Feng, Hebing Hu

Acta Pharm Sin B· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of Novel Dual-Target Estrogen Receptor α Degraders with Tubulin Inhibitory Activity for the Treatment of Endocrine-Resistant Breast Cancer.
Xiangping Deng, Xiaofei Deng, Wentao Ning, Lilan Xin, Qiuzi Li

J Med Chem· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-guided identification of novel dual-targeting estrogen receptor α degraders with aromatase inhibitory activity for the treatment of endocrine-resistant breast cancer.
Lilan Xin, Jian Min, Hebing Hu, Yuanyuan Li, Chuanqian Du, Xiaofei Deng, Xiangping Deng

Eur J Med Chem· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a Novel Class of PROTACs as Potent and Selective Estrogen Receptor α Degraders to Overcome Endocrine-Resistant Breast Cancer and .
Baohua Xie, Zhinang Yin, Zhiye Hu, Junhui Lv, Chuanqian Du, Xiangping Deng

J Med Chem· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel selective estrogen receptor degrader induces cell cycle arrest in breast cancer via ERα degradation and the autophagy-lysosome pathway.
Jiawei Zhou, Rong Shen, Jing Liu, Xiangping Deng, Lilan Xin

Bioorg Med Chem· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Novel Bicyclic Phenylselenyl-Containing Hybrids: An Orally Bioavailable, Potential, and Multiacting Class of Estrogen Receptor Modulators against Endocrine-Resistant Breast Cancer.
Xiangping Deng, Baohua Xie, Qiuzi Li, Yuan Xiao, Zhiye Hu, Xiaofei Deng

J Med Chem· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Estrogen Receptor β-Targeted Near-Infrared Inherently Fluorescent Probe: A Potent Tool for Estrogen Receptor β Research.
Qiuyu Meng, Baohua Xie, Huiguang Yu, Kang Shen, Xiangping Deng

ACS Sens· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FB-15 inhibits MGC-803 cells growth by regulating energy metabolism.
Xiangping Deng, Yiyuan Pi, Zhongli Li, Runde Xiong, Juan Liu

Chem Biol Interact· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and biological evaluation of novel 5,6,7-trimethoxy flavonoid salicylate derivatives as potential anti-tumor agents.
Renbo Liu, Xiangping Deng, Yijiao Peng, Wanshi Feng, Runde Xiong

Bioorg Chem· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design, synthesis and biological evaluation of tryptamine salicylic acid derivatives as potential antitumor agents.
Runde Xiong, Dongxiu He, Xiangping Deng, Juan Liu, Xiaoyong Lei

Medchemcomm· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A pH-sensitive prodrug strategy to co-deliver DOX and TOS in TPGS nanomicelles for tumor therapy.
Shujuan Xiong, Zhe Wang, Juan Liu, Xiangping Deng, Runde Xiong

Colloids Surf B Biointerfaces· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FS-7 inhibits MGC-803 cells growth in vitro and in vivo via down-regulating glycolysis.
Xiangping Deng, Zhongli Li, Runde Xiong, Juan Liu, Renbo Liu

Biomed Pharmacother· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design, synthesis and broad-spectrum Bcr-Abl inhibitory activity of novel thiazolamide-benzamide derivatives.
Juan Liu, Honglin Huang, Xiangping Deng, Runde Xiong, Xuan Cao

RSC Adv· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis